<DOC>
	<DOCNO>NCT00213694</DOCNO>
	<brief_summary>Clinical response chemotherapy . Biological parameter ( PSA ) RECIST evaluation . Association Docetaxel ( J 15 ) Celecoxib .</brief_summary>
	<brief_title>PROSTACOX : Metastatic Prostate Chemotherapy</brief_title>
	<detailed_description>Association Docetaxel ( J 15 ) celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>metastatic prostate cancer ASCO progression criterion prostate chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>